U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H10FN3O4
Molecular Weight 243.1918
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUROCITABINE

SMILES

[H][C@@]12OC3=NC(=N)C(F)=C[N@]3[C@]1([H])O[C@H](CO)[C@H]2O

InChI

InChIKey=PAYBYKKERMGTSS-MNCSTQPFSA-N
InChI=1S/C9H10FN3O4/c10-3-1-13-8-6(5(15)4(2-14)16-8)17-9(13)12-7(3)11/h1,4-6,8,11,14-15H,2H2/t4-,5-,6+,8-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/348088

Flurocitabine is an anti-metabolite that was developed by Hoffmann-La Roche for the treatment of cancer. The drug is metabolized to 2 biologically active substances, AFC (1-beta-D-arabinofuranosyl-5-fluorocytosine) and AFU (arabinofuranosyl-5-fluorouracil). Flurocitabine was tested against stomach cancer, pancreatic cancer, small cell lung cancer and AML, however, the development was terminated in the early phases.

Originator

Curator's Comment: # Hoffmann-La Roche Ltd

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans.
1975 Sep
Comparative ultrastructure of submaxillary salivary glands from mice treated with cytosine arabinoside, cyclocytidine, and anhydro-ara-5-fluorocytidine.
1976 Jul
Phase I study of weekly administration of anhydroara-5-fluorocytidine (NSC-166641).
1976 Mar
Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group.
1978 Feb
Phase I and II clinical study of anhydro-ara-5-fluorocytosine (AAFC) and ICRF-159 combination in adenocarcinoma of digestive origin.
1978 Winter
Anhydro-ara-5-fluorocytidine (AAFC) in gastrointestinal cancer. A phase II study.
1980
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://ascopubs.org/doi/pdf/10.1200/jco.1992.10.3.484
The maximum tolerated dose is 650 mg/m2 I.V. weekly (stomach cancer). In acute nonlymphocytic leukemia the dose is 800 mg/m2 (600mg/m2 in children) given every 12 hours until marrow hypocellularity is achieved. In Small-Cell Lung Cancer the dose is 15-20 mg/m2 IV given daily for 5 days every 3 weeks or 33-40 mg/m2 IV given weekly.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
FLUROCITABINE
INN   USAN  
INN   USAN  
Official Name English
(2R,3R,3AS,9AR)-7-FLUORO-2,3,3A,9A-TETRAHYDRO-3-HYDROXY-6-IMINO-6H-FURO(2',3':4,5)OXAZOLO(3,2-A)PYRIMIDINE-2-METHANOL
Common Name English
CYCLO FC
Common Name English
6H-FURO(2',3';4,5)OXAZOLO(3,2-A)PYRIMIDINE-2-METHANOL, 7-FLUORO-2,3,3A,9A-TETRAHYDRO-3-HYDROXY-6-IMINO-, (2R-(2.ALPHA.,3.BETA.,3A.BETA.,9A.BETA.))-
Common Name English
5-FLUOROCYCLOCYTIDINE
Common Name English
AAFC
Common Name English
FLUROCITABINE [USAN]
Common Name English
flurocitabine [INN]
Common Name English
RO-210702
Code English
6H-FURO(2',3':4,5)OXAZOLO(3,2-A)PYRIMIDINE-2-METHANOL, 7-FLUORO-2,3,3A,9A-TETRAHYDRO-3-HYDROXY-6-IMINO-, (2R,3R,3AS,9AR)-
Systematic Name English
2,2'-ANHYDRO-5-FLUORO-1-.BETA.-D-ARABINOFURANOSYLCYTOSINE
Common Name English
ANHYDRO-ARABINOSYL-5-FLUORO-CYTOSINE
Common Name English
5'-FLUOROCYCLOCYTIDINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1557
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
Code System Code Type Description
CAS
37717-21-8
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
FDA UNII
89TPE33M27
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
SMS_ID
100000080931
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
INN
4335
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
PUBCHEM
3034016
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
NCI_THESAURUS
C2343
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
ECHA (EC/EINECS)
253-638-9
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
MESH
C011168
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
EVMPD
SUB07748MIG
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
ChEMBL
CHEMBL472561
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID401317496
Created by admin on Sat Dec 16 17:41:16 GMT 2023 , Edited by admin on Sat Dec 16 17:41:16 GMT 2023
PRIMARY